Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Operating Leases (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Operating Leases data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 18.26% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, down 18.26%, while the annual FY2024 figure was $1.3 million, 6.83% up from the prior year.
  • Operating Leases reached $1.2 million in Q3 2025 per TLSI's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $1.6 million in Q4 2022 and bottomed at $1.2 million in Q2 2024.
  • Average Operating Leases over 4 years is $1.3 million, with a median of $1.3 million recorded in 2025.
  • Peak YoY movement for Operating Leases: dropped 21.91% in 2023, then increased 14.26% in 2024.
  • A 4-year view of Operating Leases shows it stood at $1.6 million in 2022, then fell by 21.91% to $1.2 million in 2023, then grew by 6.83% to $1.3 million in 2024, then fell by 7.37% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.2 million in Q3 2025, $1.3 million in Q2 2025, and $1.3 million in Q1 2025.